Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

77.19 +1.94 (+2.57%)
Streaming Delayed Price Updated: 1:18 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge ↗
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products. 
Via Benzinga
News headline image
Ionis reports first quarter 2025 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For April 30, 2025 ↗
 
Via Benzinga
News headline image
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' ↗
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead. 
Via Benzinga
News headline image
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Competitive Analysis In The ATTR-CM Field ↗
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal ↗
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales. 
Via Benzinga
News headline image
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharma Beats Expectations for Q4 ↗
The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss. 
Via The Motley Fool
News headline image
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales ↗
Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million. 
Via Benzinga
News headline image
Ionis reports fourth quarter and full year 2024 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold fourth quarter and full year 2024 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA 
From Biogen Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025. 
Via Benzinga
News headline image
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.